NYXOID

This brand name is authorized in Austria, Australia, Estonia, Croatia, Ireland, Italy, Lithuania, New Zealand, Poland, Romania, United Kingdom

Active ingredients

The drug NYXOID contains one active pharmaceutical ingredient (API):

1 Naloxone UNII 5Q187997EE - NALOXONE HYDROCHLORIDE DIHYDRATE

Naloxone hydrochloride, a semisynthetic morphine derivative (N-allyl-nor-oxymorphone), is a specific opioid antagonist that acts competitively at opioid receptors. It reveals very high affinity for the opioid receptor sites and therefore displaces both opioid agonists and partial antagonists, such as pentazocine, for example, but also nalorphine. Read about Naloxone

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
NYXOID Nasal spray	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
V03AB15	Naloxone	V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AB Antidotes
Discover more medicines within V03AB15

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11816X, 11817Y
Country: EE	Ravimiamet	Identifier(s): 1756773
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 357442
Country: IT	Agenzia del Farmaco	Identifier(s): 045777012
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1084451
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 20367, 21656
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100399996
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W66685001